FindMyKOL
Clinical trialNCT04041843CompletedPhase 2Interventional

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

SponsorNew York Medical CollegeEnrollment25Venous Thromboembolism
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • New York Medical College

    Valhalla, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Apixaban →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
2 Jun 2017
Primary completion
31 May 2021
Completion
31 May 2022
Last update posted
25 Oct 2022
Registered enrollment
25
Registry id
NCT04041843
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.